Manufacturing, Expression Systems

Choosing the Right Expression System for Complex Modalities

July 02, 2023

The choice of expression system requires wise consideration of product complexities.

Lonza Invests in Microbial Development Lab Expansion

November 18, 2021

Lonza is expanding its microbial development capabilities at its Visp, Switzerland, site to support clinical and commercial drug development programs.

KGI Team Adapts Vaccine Development Work to Address COVID-19

August 12, 2021

A research team at the Keck Graduate Institute will work to adapt its decade-long low-cost vaccine R&D for developing countries into a COVID-19 vaccine.

Catalent Biologics Launches New Cell Line Expression Technology

July 22, 2021

Catalent Biologics has launched its new cell line expression technology, GPEx Lightning, which aims to shorten drug substance development timelines by up to three months.

Thermo Fisher Scientific’s Clinic Solution Aims to Accelerate Biologic Drug Development

June 30, 2021

Thermo Fisher Scientific has introduced its new Quick to Clinic solution, which is designed to accelerate biologic drug development from discovery to the IND phase in a shortened period.

MilliporeSigma Launches Lentiviral Production Platform for Cell and Gene Therapies

October 16, 2020

The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.

Synthetic Biology Offers a Solution to Cell Therapy Source Material Constraints

October 02, 2020

An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.

iBio and Planet Biotechnology Partner to Develop COVID-19 Therapeutic

September 02, 2020

The companies will collaborate on the production of a novel anti-SARS-CoV-2 immunoadhesin in iBio’s FastPharming manufacturing system.

GigaGen Highlights Research Describing New Class of Drugs for Potential COVID-19 Therapy

August 28, 2020

In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.

MilliporeSigma Adds Viral Vector and Gene Therapy Capacity

April 21, 2020

The company will build an additional commercial-scale, contract manufacturing facility for viral vectors and gene therapies near its existing site in Carlsbad, CA.